Merck Announces Expanded Co-Pay Assistance Program for Isentress (Raltegravir)
Enhanced Program Provides Assistance to People Living With HIV-1 Who Are Privately Insured and Have Out-of-Pocket Co-Pays
October 22, 2010
Whitehouse Station, N.J. -- Merck today announced an enhanced co-pay assistance program for people living with HIV-1 who are taking the Company's first-in-class HIV-1 integrase inhibitor, ISENTRESS® (raltegravir) Tablets. The program provides important savings for privately-insured patients with out-of-pocket costs for ISENTRESS, and is part of Merck's ongoing commitment to providing access to treatment.
People who have been prescribed ISENTRESS who meet certain requirements are eligible to participate in the program, in which they can receive a Savings Coupon for up to $400 toward out-of-pocket costs on each of up to 12 eligible prescriptions of ISENTRESS, regardless of the number of tablets supplied on the prescription. The program applies to eligible patients who have private health insurance with a co-payment for the prescription. Savings are limited to co-pay amount and eligibility restrictions, terms and conditions apply.View Full Article
Add Your Comment:
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)